Persistent hypogammaglobulinemia after rituximab therapy in pediatric patients, prevalence and clinical outcomes: Hypogammaglobulinemia After Rituximab in Children

Publication date

2025-06

Authors

Höppener, Susanna P.C.
Veldkamp, Saskia R.ORCID 0000-0002-1626-353X
de Groot, Mark C HORCID 0000-0002-5764-5788
Haitjema, SaskiaORCID 0000-0001-5465-4868
Drylewicz, JuliaORCID 0000-0002-9434-8459ISNI 0000000357090505
Boelens, Jaap JanISNI 0000000396746028
Lindemans, CarolineISNI 0000000388582537
Van Montfrans, Joris M.ISNI 0000000387128439
van Royen-Kerkhof, AnnetISNI 000000039500070X
Jansen, Marc

Editors

Advisors

Supervisors

Document Type

Article

Collections

Open Access logo

License

cc_by

Abstract

Hypogammaglobulinemia is a known side effect of rituximab (RTX) in adults, but its prevalence and persistence in children remain underexplored. This retrospective cohort study at a tertiary care center examines the prevalence and clinical outcomes of hypogammaglobulinemia in pediatric patients after RTX therapy. Patients aged ≤ 18 years treated with RTX for various indications between 2000 and 2020 were included. Patients were classified as having hypogammaglobulinemia when (1) IgG levels were <-2SD below reference for age, or (2) when they received immunoglobulin replacement therapy (IGRT) for the indication hypogammaglobulinemia. Hypogammaglobulinemia after RTX treatment was observed in 74/134 patients (55.2 %). Persistent hypogammaglobulinemia (>6 months) was observed in 46/91 patients (50.5 %), of whom 9 patients remained hypogammaglobulinemic >5 years. Low baseline IgG and IgM levels were significantly associated with persistent hypogammaglobulinemia, while patients receiving RTX therapy for autoimmune diseases were less frequently affected. CD19+ B cells reconstituted in a median of 11 months (IQR=[7.3–18.0]), while CD19+CD27+IgG+ switched memory B cells took significantly longer, with a median of 1.8 years (IQR=[1.0–2.9]). Three patients developed class-switch recombination-deficiencies and never recovered. Recurrent infections, of which two fatal, were recorded in 18 patients and were significantly more prevalent in those with persistent hypogammaglobulinemia. In conclusion, over half of children had low IgG levels and/or required IGRT for hypogammaglobulinemia following RTX therapy. Persistent hypogammaglobulinemia was associated with low pre-RTX IgG and/or IgM levels. Children with hypogammaglobulinemia after RTX are often IGRT-dependent, experience recurrent (and sometimes fatal) infections, and may develop secondary immunoglobulin class-switch defects.

Keywords

B cell reconstitution, Hypogammaglobulinemia, Pediatric, Rituximab, Immunology and Allergy, Immunology, Journal Article

Citation

Höppener, S P C, Veldkamp, S R, de Groot, M C H, Haitjema, S, Drylewicz, J, Boelens, J J, Lindemans, C A, van Montfrans, J, van Royen-Kerkhof, A & Jansen, M H A 2025, 'Persistent hypogammaglobulinemia after rituximab therapy in pediatric patients, prevalence and clinical outcomes : Hypogammaglobulinemia After Rituximab in Children', Clinical Immunology Communications, vol. 7, pp. 55-63. https://doi.org/10.1016/j.clicom.2025.04.001